Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
50.25    -4.00 (-7.55%)
Bid:
49.50
Ask:
51.00
Spread: 1.50 (3.03%)
Market Cap: £94.01m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Trading Update

13 Oct 2016 07:00

RNS Number : 4035M
Iofina PLC
13 October 2016
 

 

13 October 2016

 

Iofina plc

("Iofina", the "Group" or the "Company")

(LSE AIM: IOF)

 

Q3 Production & Corporate Update

On track to meet production targets for H2 2016

 

Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, is pleased to update the market today on the Company's Q3 iodine production.

The Group produced 125.1 metric tonnes ("MT") of crystalline iodine in Q3 2016 (the "Period"), and has produced 380.7 MT year to date from our five IOsorb® plants in Oklahoma. The Group remains on track to meet our production targets of 250-270 MT of crystalline iodine in H2 2016. As recently communicated, Iofina and its partners have completed improvement projects at three plants during the Period. The design improvements will provide a more consistent brine input to our IOsorb® plants, which is necessary under a changing regulatory environment. Iofina continues to work closely with its partners on a variety of strategies to maximise productive throughput at all of its IOsorb® plants.

In addition, Iofina Chemical has performed well in a competitive market, selling the Company's IOflo® iodine along with Iofina's portfolio of iodine and specialty halogen derivatives, to customers worldwide. 

 

Commenting on today's update, President and CEO Dr. Tom Becker, stated:

"Our five IOsorb® plants continue to produce on a reliable basis in line with Company forecasts. Improvements to brine tie-ins and other measures will help ensure consistency of raw brine for the future."

 

For further information, please contact:

 

Dr. Tom Becker, CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Giles Rolls/Joanna Scott

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Dominic Barretto/Harriet Jackson

Yellow Jersey PR Limited

Tel: +44 (0)7544 275 882

 

About Iofina:

Iofina specialises in the exploration and production of iodine, iodine specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® IOsorb® technology. Iofina has operations in the United States, specifically in Montana, Kentucky and Oklahoma. It has complete vertical integration from the production of iodine in the field to the manufacture of the chemical end-products derived from iodine to the consumer and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilises its portfolio of patented and patent pending technology, proprietary methods and trademarks throughout all business lines.

www.iofina.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLLFLDIILFLIR
Date   Source Headline
23rd Sep 20214:35 pmRNSPrice Monitoring Extension
22nd Sep 20219:58 amRNSHolding(s) in Company
10th Sep 20214:15 pmRNSHolding(s) in Company
10th Sep 20213:25 pmRNSHolding(s) in Company
15th Jul 20217:00 amRNSH1 2021 Update
18th Jun 20214:36 pmRNSPrice Monitoring Extension
18th Jun 20213:20 pmRNSResult of AGM
27th May 20214:40 pmRNSSecond Price Monitoring Extn
27th May 20214:36 pmRNSPrice Monitoring Extension
27th May 20212:06 pmRNSSecond Price Monitoring Extn
27th May 20212:00 pmRNSPrice Monitoring Extension
27th May 202111:06 amRNSSecond Price Monitoring Extn
27th May 202111:00 amRNSPrice Monitoring Extension
27th May 20217:00 amRNSHolding(s) in Company
25th May 20217:00 amRNSAnnual Financial Report
21st May 20215:50 pmRNSNotice of Results
15th Apr 20217:00 amRNSQ1 2021 Update
1st Mar 20215:36 pmRNSDirector/PDMR Shareholding
24th Feb 20217:00 amRNSDirector/PDMR Shareholding
19th Feb 20217:00 amRNSDirector/PDMR Shareholding
19th Jan 20217:00 amRNSMarket Update
22nd Dec 20204:41 pmRNSSecond Price Monitoring Extn
22nd Dec 20204:35 pmRNSPrice Monitoring Extension
22nd Dec 20202:05 pmRNSSecond Price Monitoring Extn
22nd Dec 20202:00 pmRNSPrice Monitoring Extension
16th Dec 202011:50 amRNSGrant of Share Options
16th Oct 20207:00 amRNSQ3 2020 Update
13th Oct 20204:40 pmRNSSecond Price Monitoring Extn
13th Oct 20204:35 pmRNSPrice Monitoring Extension
29th Sep 20207:00 amRNSINTERIM RESULTS
23rd Sep 20207:09 amRNSPrice Monitoring Extension
23rd Sep 20207:07 amRNSSecond Price Monitoring Extn
23rd Sep 20207:04 amRNSPrice Monitoring Extension
23rd Sep 20207:01 amRNSSecond Price Monitoring Extn
22nd Sep 20204:41 pmRNSSecond Price Monitoring Extn
22nd Sep 20204:36 pmRNSPrice Monitoring Extension
22nd Sep 20202:05 pmRNSSecond Price Monitoring Extn
22nd Sep 20202:00 pmRNSPrice Monitoring Extension
22nd Sep 20207:00 amRNSDebt Refinancing Signed
26th Aug 20207:00 amRNSDebt Update
31st Jul 20208:00 amRNSLaunch of new website
22nd Jul 202011:06 amRNSSecond Price Monitoring Extn
22nd Jul 202011:00 amRNSPrice Monitoring Extension
22nd Jul 20207:00 amRNSCorporate Update
30th Jun 20202:36 pmRNSDebt Update
30th Jun 202011:52 amRNSResult of AGM
26th Jun 20201:26 pmRNSChange of venue for AGM on 30 June 2020
26th Jun 20207:00 amRNSIO#8 and Debt Update
27th May 20207:00 amRNSFinal Results
19th May 20204:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.